JP2020506879A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506879A5
JP2020506879A5 JP2019531279A JP2019531279A JP2020506879A5 JP 2020506879 A5 JP2020506879 A5 JP 2020506879A5 JP 2019531279 A JP2019531279 A JP 2019531279A JP 2019531279 A JP2019531279 A JP 2019531279A JP 2020506879 A5 JP2020506879 A5 JP 2020506879A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
heterocycloalkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019531279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506879A (ja
JP6982716B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/012748 external-priority patent/WO2018132326A1/en
Publication of JP2020506879A publication Critical patent/JP2020506879A/ja
Publication of JP2020506879A5 publication Critical patent/JP2020506879A5/ja
Application granted granted Critical
Publication of JP6982716B2 publication Critical patent/JP6982716B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019531279A 2017-01-10 2018-01-08 複素環式化合物及びその使用 Active JP6982716B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444601P 2017-01-10 2017-01-10
US62/444,601 2017-01-10
PCT/US2018/012748 WO2018132326A1 (en) 2017-01-10 2018-01-08 Heterocyclic compounds and use thereof

Publications (3)

Publication Number Publication Date
JP2020506879A JP2020506879A (ja) 2020-03-05
JP2020506879A5 true JP2020506879A5 (enExample) 2021-01-14
JP6982716B2 JP6982716B2 (ja) 2021-12-17

Family

ID=62839630

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531279A Active JP6982716B2 (ja) 2017-01-10 2018-01-08 複素環式化合物及びその使用

Country Status (10)

Country Link
US (1) US10882854B2 (enExample)
EP (1) EP3568137A4 (enExample)
JP (1) JP6982716B2 (enExample)
KR (1) KR102335082B1 (enExample)
CN (1) CN110381949B (enExample)
AU (1) AU2018208366B2 (enExample)
CA (1) CA3047146C (enExample)
RU (1) RU2756055C2 (enExample)
TW (1) TWI664174B (enExample)
WO (1) WO2018132326A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110176278B (zh) * 2019-05-24 2021-09-28 河海大学 氨基酸氯化生成二氯乙腈的连续反应动力学模型建模方法
CA3228210A1 (en) * 2021-08-02 2023-02-09 National Health Research Institutes Pyrimidine compounds and use thereof
TW202345843A (zh) * 2022-04-06 2023-12-01 財團法人國家衛生研究院 脂質奈米顆粒及脂質體

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW550258B (en) * 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
WO2004052862A1 (ja) 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
US20060281712A1 (en) 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
MX2008016523A (es) 2006-06-30 2009-01-19 Astrazeneca Ab Derivados de pirimidina utiles en el tratamiento de cancer.
EP2043651A2 (en) * 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
EP2268635B1 (en) 2008-04-21 2015-06-10 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
BR112017005713B1 (pt) * 2014-09-22 2023-09-26 National Health Research Institutes Composto de fórmula (i) e composição farmacêutica

Similar Documents

Publication Publication Date Title
JP2010511721A5 (enExample)
JP2022510313A5 (enExample)
JP2016053042A5 (enExample)
JP2012508252A5 (enExample)
JP2021512150A5 (enExample)
JP2011522789A5 (enExample)
RU2015143841A (ru) Ингибиторы hdac
JP2009531376A5 (enExample)
JP2018507877A5 (enExample)
JP2016516043A5 (enExample)
JP2017511305A5 (enExample)
JP2009500347A5 (enExample)
JP2018535967A5 (enExample)
JP2017530193A5 (enExample)
JP2009516697A5 (enExample)
JP2011037841A5 (enExample)
AR067896A1 (es) Procedimiento para sintetizar compuestos utiles para tratar hepatitis c
JP2011513410A5 (enExample)
JP2019529419A5 (enExample)
JP2011509949A5 (enExample)
JP2017532360A5 (enExample)
JP2016513681A5 (enExample)
JP2022525069A5 (enExample)
JP2011523952A5 (enExample)
JP2009538336A5 (enExample)